MedTrace Logo

Vasoconstriction Trial With LEO 90100 Aerosol Foam

NCT02973776 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-05-09

No results posted yet for this study

Summary

Vasoconstriction study with LEO 90100

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 90100 aerosol foam

DRUG

Dermoval®/Dermovate®

DRUG

Diprosone

DRUG

Elocon

DRUG

Locoid

OTHER

LEO 90100 foam vehicle

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02973776 on ClinicalTrials.gov